Lantheus Holdings, Inc. (NASDAQ:LNTH) is one of the best high growth healthcare stocks to buy now. On March 17, Jefferies lifted the price target on Lantheus Holdings, Inc. (NASDAQ:LNTH) to $110 from $105, reaffirming a Buy rating on the shares. The firm stated that after comments at a recent conference and a meeting with the company, it is updating its prostate-specific membrane antigen positron emission tomography, or PSMA PET, model and Lantheus Holdings, Inc.’s (NASDAQ:LNTH) pricing assumptions. Jefferies further stated that it now models PSMA PET market volume growth of roughly 20% in 2025 and 10%-11% in 2026, and PYLARIFY TruVu commercial rollout in 4Q26, with meaningful contribution in 2027 and beyond.

The rating update came the same day Lantheus Holdings, Inc. (NASDAQ:LNTH) announced that the U.S. Food and Drug Administration extended its review of the New Drug Application for LNTH-2501 (Gallium 68 edotreotide) by three months to June 29, 2026, with the extension not related to the efficacy or safety data of LNTH-2501.

Lantheus Holdings, Inc. (NASDAQ:LNTH) provides diagnostic imaging and nuclear medicine products, developing products that support healthcare professionals in patient management and outcomes and help clinicians detect cardiovascular disease. The company’s operations are divided into the U.S. and International geographical segments.

While we acknowledge the potential of LNTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.